EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Early-Onset Type 2 Diabetes and Tirzepatide Treatment: A Post Hoc Analysis From the SURPASS Clinical Trial Program

Philip Zeitler, Rodolfo J Galindo, Melanie J Davies, Brandon K Bergman, Vivian T Thieu, Claudia Nicolay, Sheryl Allen, Robert J Heine, Clare J Lee iD

Diabetes Care · 01.06.2024 · 47 (6) · 1056-1064

DOI: 10.2337/dc23-2356 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes Care, online erschienen am 19.04.2024. Verfasst von Philip Zeitler und 8 weiteren Autor:innen. Beteiligte Einrichtung: Children's Hospital Colorado, University of Colorado Anschutz Medical Campus, Aurora, CO. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemic Agents. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE We evaluated baseline characteristics of participants with early-onset type 2 diabetes (T2D) from the SURPASS program and tirzepatide’s effects on glycemic control, body weight (BW), and cardiometabolic markers. RESEARCH DESIGN AND METHODS This post hoc analysis compared baseline characteristics and changes in mean HbA1c, BW, waist circumference (WC), lipids, and blood pressure (BP) in 3,792 participants with early-onset versus later-onset T2D at week 40 (A Study of Tirzepatide [LY3298176] in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone [SURPASS-1] and A Study of Tirzepatide [LY3298176] Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes [SURPASS-2]) or week 52 (A Study of Tirzepatide [LY3298176] Versus Insulin Degludec in Participants With Type 2 Diabetes [SURPASS-3]). Analyses were performed by study on data from participants while on assigned treatment without rescue medication in case of persistent hyperglycemia. RESULTS At baseline in SURPASS-2, participants with early-onset versus later-onset T2D were younger with longer diabetes duration (9 vs. 7 years, P < 0.001) higher glycemic levels (8.5% vs. 8.2%, P < 0.001), higher BW (97 vs. 93 kg, P < 0.001) and BMI (35 vs. 34 kg/m2, P < 0.001), and a similarly abnormal lipid profile (e.g., triglycerides 167 vs. 156 mg/dL). At week 40, similar improvements in HbA1c (−2.6% vs. −2.4%), BW (−14 vs. −13 kg), WC (−10 vs. −10 cm), triglycerides (−26% vs. −24%), HDL (7% vs. 7%), and systolic BP (−6 vs. −7 mmHg) were observed in both subgroups with tirzepatide. CONCLUSIONS Despite younger age, participants with early-onset T2D from the SURPASS program had higher glycemic levels and worse overall metabolic health at baseline versus those with later-onset T2D. In this post hoc analysis, similar improvements in HbA1c, BW, and cardiometabolic markers were observed with tirzepatide, irrespective of age at T2D diagnosis. Future studies are needed to determine long-term outcomes of tirzepatide in early-onset T2D.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Hypoglycemic AgentsHumansMaleFemaleMiddle AgedAdultGlycated HemoglobinBlood GlucoseBlood PressureBody WeightGlucagon-Like Peptide-2 ReceptorGastric Inhibitory PolypeptideTirzepatide

Substanzen

Hypoglycemic AgentsGlycated HemoglobinBlood GlucoseGlucagon-Like Peptide-2 ReceptorGastric Inhibitory PolypeptideTirzepatide

Autor:innen und Institutionen

  • Children's Hospital Colorado, University of Colorado Anschutz Medical Campus, Aurora, CO.
  • University of Miami Miller School of Medicine, Miami, FL.
  • Diabetes Research Centre, University of Leicester and the Leicester NIHR Biomedical Research Centre, Leicester General Hospital, Leicester, U.K.
  • Eli Lilly and Company, Indianapolis, IN.

ORCID-Profile: Clare J Lee

Förderung

  • Eli Lilly and Company

Zitieren

APA

Zeitler, P., Galindo, R. J., Davies, M. J., Bergman, B. K., Thieu, V. T., Nicolay, C., Allen, S., Heine, R. J., & Lee, C. J. (2024). Early-Onset Type 2 Diabetes and Tirzepatide Treatment: A Post Hoc Analysis From the SURPASS Clinical Trial Program. Diabetes Care, 47(6), 1056-1064. https://doi.org/10.2337/dc23-2356

Vancouver

Zeitler P, Galindo RJ, Davies MJ, Bergman BK, Thieu VT, Nicolay C, et al. Early-Onset Type 2 Diabetes and Tirzepatide Treatment: A Post Hoc Analysis From the SURPASS Clinical Trial Program. Diabetes Care. 2024;47(6):1056-1064. doi:10.2337/dc23-2356

BibTeX
@article{Zeitler2024,
  author = {Zeitler, Philip and Galindo, Rodolfo J and Davies, Melanie J and Bergman, Brandon K and Thieu, Vivian T and Nicolay, Claudia and Allen, Sheryl and Heine, Robert J and Lee, Clare J},
  title = {Early-Onset Type 2 Diabetes and Tirzepatide Treatment: A Post Hoc Analysis From the SURPASS Clinical Trial Program},
  journal = {Diabetes Care},
  year = {2024},
  volume = {47},
  number = {6},
  pages = {1056--1064},
  doi = {10.2337/dc23-2356}
}
Kostenlos starten →